Synbio Technologies is founded by professionals with extensive experience in scientific research and industrial management. The company has developed a cutting-edge DNA synthesis technology consisting of the Syno® 1.0, Syno® 2.0 and Syno® 3.0. Through our distinctive Syno® platforms, we can satisfy customers’ needs, including construction of a humanized antibody library, optimization of industrial enzymes, chromosome/genome synthesis, development of genetic engineering vaccines and DNA informatics storage technology.

Synbio Technologies has further developed “GPS” – an advanced biotechnology transformation and application platform-based on the Syno® synthesis technology. The innovative “GPS” platform follows the biological central dogma and expands genotype, phenotype and synotype effectively to achieve the one stop solution of gene “design-construction-application”.

The company’s scientific capabilities encompass areas such as DNA engineering, DNA synthesis, genome synthesis, pathway synthesis, synthetic biology, pharmacogenomics, microbiology, translational biology and the applications of synthetic biology. Synbio Technologies’ team has a proven track record regarding translating scientific breakthroughs into cost effective biological solution.